文献速递前列腺癌

固定疗程全身治疗联合转移灶定向放疗用于寡转移性激素敏感性前列腺癌

Combined Fixed-duration Systemic Treatment and Metastasis-directed Radiotherapy for Oligometastatic Hormone-sensitive Prostate Cancer.
PubMed 文献 · Eur Urol Oncol · 2024-11-14

本研究回顾性纳入89例寡转移性激素敏感性前列腺癌患者,均接受固定疗程全身治疗联合转移灶定向放疗(原发灶视情况接受局部治疗),全身治疗结束时PSA≤0.1 ng/ml。中位随访37个月,3年临床无进展生存率为45%,中位性腺功能正常无进展生存期为12个月,中位重启ADT时间为47个月。全身治疗时长≥12个月是唯一显著预测更好结局的因素。

要点

  • 完成固定疗程全身治疗联合转移灶定向放疗后,45%的患者3年时仍无临床进展。
  • 中位重启ADT时间为47个月,60%的患者3年时尚未重启ADT。
  • 全身治疗时长≥12个月是唯一显著预测更好结局的因素。

核心结论

  • 在接受全程治疗的寡转移性激素敏感性前列腺癌患者中,45%在完成治疗后3年仍无进展,提示该策略在部分患者中可能实现长期缓解甚至治愈。
  • 需要前瞻性试验来评估该治疗策略。

研究设计与样本

  • 回顾性单机构队列研究,连续纳入经传统影像或分子影像确认的寡转移性激素敏感性前列腺癌患者,均接受全程治疗(雄激素剥夺治疗±雄激素受体通路抑制剂、转移灶定向治疗,以及原发灶的局部治疗(若为初发转移)),且全身治疗完成时前列腺特异性抗原≤0.1 ng/ml。
  • 共纳入89例患者,其中23例为初发寡转移性前列腺癌;中位转移灶数目为1个;43例(48%)通过分子影像检出疾病。
  • 49例(55%)接受ADT+ARPI双药治疗,40例(45%)接受ADT单药治疗。

主要发现

  • 中位随访37个月,共发生46例临床无进展生存事件;3年临床无进展生存率为45%(95%CI 33-56),中位性腺功能正常无进展生存期为12个月。
  • 中位重启ADT时间为47个月,60%的患者3年时尚未重启ADT。
  • 全身治疗时长≥12个月是唯一显著预测更好结局的因素。

局限性

  • 回顾性单机构队列研究。
  • 需要前瞻性试验来评估该治疗策略。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVE: It is unclear whether "total therapy" (androgen deprivation therapy [ADT] with or without an androgen receptor pathway inhibitor [ARPI], metastasis-directed therapy, and local therapy to the prostate if de novo) may lead to long-term durable remission in oligometastatic hormone-sensitive prostate cancer (omHSPC). This study aims to evaluate the outcomes after the completion of total therapy in patients with omHSPC. METHODS: A retrospective single-institution cohort of consecutive patients with omHSPC identified on conventional or molecular imaging treated with total therapy was assembled. All patients had prostate-specific antigen ≤0.1 ng/ml at the completion of systemic therapy. Kaplan-Meier and Cox regression models were used to evaluate the key outcomes of interest: clinical progression-free survival (cPFS), eugonadal progression-free survival (PFS), and time to restart of ADT (TTrADT). KEY FINDINGS AND LIMITATIONS: Eighty-nine patients were included, of whom 23 were with de novo omHSPC; the median number of metastases was 1, and detection of disease by molecular imaging was performed in 43 patients (48%). Forty-nine patients (55%) received ADT + ARPI doublet and 40 (45%) received ADT alone. At a median follow-up of 37 mo, there were 46 cPFS events; 3-yr cPFS rate was 45% (95% confidence interval 33-56) and the median eugonadal PFS was 12 mo. The median TTrADT was 47 mo, and 60% had not restarted ADT at 3 yr. Duration of systemic therapy ≥12 mo was the only significant predictor of better outcomes. CONCLUSIONS AND CLINICAL IMPLICATIONS: Of the patients receiving total therapy for omHSPC, 45% remained progression free at 3 yr after completing therapy, hinting at the potential for long-term remission and possible cure with this strategy in a subset of patients with omHSPC. Prospective trials evaluating this approach are needed. PATIENT SUMMARY: In this report, we looked at outcomes in men who had received a fixed duration of hormonal therapy along with radiotherapy to metastatic sites (and prostate radiotherapy or surgery in those with newly diagnosed disease) for oligometastatic prostate cancer. We found that nearly half of the patients had no evidence of cancer recurrence at 3 yr after completing therapy, and 60% had not resumed any therapy at this time point.

来源:Eur Urol Oncol,查看原文。版权归原作者所有。

引用

  1. Ravi P, Zhong C, Xie W, et al. Combined Fixed-duration Systemic Treatment and Metastasis-directed Radiotherapy for Oligometastatic Hormone-sensitive Prostate Cancer. Eur Urol Oncol. 2024. PMID: 39547900. doi:10.1016/j.euo.2024.10.014

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。